Physician profile
Alberto Ruvalcaba
NPI 1598074338
$705.34
in general payments reported to CMS, 2019-2025
18 companies · $241 in 2025
The $241 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $17.72 · 2022: $161 · 2023: $117 · 2024: $169 · 2025: $241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $527.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $526.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $105.31 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $101.70 | 2022-2025 | Mounjaro, Zepbound, Trulicity |
| Dexcom, INC. | $100.69 | 2022-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.26 | 2021-2024 | Jardiance |
| Medtronic, INC. | $44.66 | 2025 | Closurefast |
| Amgen INC. | $40.58 | 2022-2025 | Repatha |
| Phathom Pharmaceuticals, INC. | $29.21 | 2024-2025 | Voquezna |
| Novartis Pharmaceuticals Corporation | $28.56 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $24.24 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $24.14 | 2024 | Zoryve |
| Shield Therapeutics INC | $22.97 | 2025 | |
| Hologic Sales and Service, LLC | $22.63 | 2024 | Aptima |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.90 | 2025 | Caplyta |
| Pfizer INC. | $20.15 | 2024 | |
| Amneal Pharmaceuticals LLC | $19.57 | 2023 | Lyvispah |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $18.68 | 2024 | |
| Organon LLC | $18.18 | 2023 | Nexplanon |
| Seqirus USA INC | $14.91 | 2025 | Fluad, Flucelvax |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alberto Ruvalcaba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.